MOLECULES TO MEDICINE Trademark

Trademark Overview

On Monday, October 21, 2019, a trademark application was filed for MOLECULES TO MEDICINE with the United States Patent and Trademark Office. The USPTO has given the MOLECULES TO MEDICINE trademark a serial number of 88662767. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Tuesday, June 4, 2024. The MOLECULES TO MEDICINE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials
molecules to medicine

General Information

Serial Number88662767
Word MarkMOLECULES TO MEDICINE
Filing DateMonday, October 21, 2019
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateTuesday, June 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 3, 2020

Trademark Statements

Goods and ServicesMedical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, October 25, 2019
Primary Code042
First Use Anywhere DateMonday, November 13, 2023
First Use In Commerce DateMonday, November 13, 2023

Trademark Owner History

Party NameNOT AVAILABLE
Party Type20 - Owner at Publication
Legal Entity Type01 - Individual
AddressLittle Rock, AR 72223
Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressLittle Rock, AR 72223

Trademark Events

Event DateEvent Description
Thursday, October 24, 2019NEW APPLICATION ENTERED
Friday, October 25, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, January 27, 2020ASSIGNED TO EXAMINER
Monday, January 27, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 12, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 3, 2020PUBLISHED FOR OPPOSITION
Tuesday, March 3, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, April 1, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Wednesday, July 1, 2020OPPOSITION INSTITUTED NO. 999999
Tuesday, February 1, 2022ASSIGNED TO EXAMINER
Saturday, April 2, 2022OPPOSITION TERMINATED NO. 999999
Saturday, April 2, 2022OPPOSITION DISMISSED NO. 999999
Saturday, April 2, 2022TTAB RELEASE CASE TO TRADEMARKS
Tuesday, May 17, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, October 26, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 26, 2022SOU EXTENSION 1 FILED
Wednesday, October 26, 2022SOU EXTENSION 1 GRANTED
Friday, October 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 16, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 16, 2023SOU EXTENSION 2 FILED
Friday, May 19, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 19, 2023SOU EXTENSION 2 GRANTED
Saturday, May 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 13, 2023SOU EXTENSION 3 FILED
Monday, November 13, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, November 14, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 15, 2024SOU EXTENSION 4 FILED
Wednesday, May 15, 2024USE AMENDMENT FILED
Wednesday, May 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 4, 2024SOU EXTENSION 4 GRANTED
Tuesday, June 4, 2024STATEMENT OF USE PROCESSING COMPLETE
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

medicine molecules trials medical clinical research scientific information field providing others namely